STRATEC SE

Interim / Quarterly Report • Aug 10, 2022

HALF-YEAR FINANCIAL REPORT H1|2022

January 1 to June 30, 2022

STRATEC designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences.

Furthermore, the company offers complex consumables for diagnostic and medical applications. For analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

Our partners market the systems, software, and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

CONTENTS

Current Information / Key Figures 04

Letter from the Board of Management 05

Interim Group Management Report 06

Consolidated Balance Sheet as of June 30, 2022 12

Consolidated Statement of Comprehensive Income for the period January 1 to June 30, 2022 14

Consolidated Statement of Comprehensive Income for the period April 1 to June 30, 2022 15

Consolidated Statement of Changes in Equity for the period January 1 to June 30, 2022 16

Consolidated Statement of Cash Flows for the period January 1 to June 30, 2022 18

Selected Explanatory Notes for the period January 1 to June 30, 2022 19

Further Information 32

CURRENT INFORMATION

• Sales in H1/2022 -11.9% to € 137.2 million (H1/2021: € 155.8 million); constant currency: -15.2%
• Adjusted EBIT of € 21.2 million in H1/2022 (H1/2021: € 34.5 million)
• Adjusted EBIT margin of 15.4% (H1/2021: 22.1%)
• Preparations for serial production are advancing successfully for a new system solution for one of the market leaders
• High volume of development activity and numerous promising negotiations for new projects
• 2022 guidance confirmed: Sales at previous year's level on constant-currency basis and adjusted EBIT margin of around 16.5% to 18.5% expected

KEY FIGURES1

€ 000s	H1/2022	H1/2021	Change	Q2/2022	Q2/2021	Change
Sales	137,193	155,765	-11.9%	61,806	83,770	-26.2%
EBITDA	27,841	40,274	-30.9%	9,382	21,434	-56.2%
EBITDA margin (%)	20.3	25.9	-560 bps	15.2	25.6	-1,040 bps
Adjusted EBIT	21,178	34,457	-38.5%	6,141	18,412	-66.6%
Adjusted EBIT margin (%)	15.4	22.1	-670 bps	9.9	22.0	-1,210 bps
Adjusted consolidated net income	16,679	28,547	-41.6%	4,731	15,400	-69.3%
Adjusted earnings per share (€)	1.38	2.36	-41.5%	0.39	1.27	-69.3%
Earnings per share (€)	1.04	2.08	-50.0%	0.12	1.12	-89.3%

bps = basis points

¹ To facilitate comparison, the figures have been adjusted to exclude amortization resulting from acquisition-related purchase price allocations and a provision recognized for expected tax back payments (including interest payments). In the previous year, the figures were also adjusted to exclude an impairment recognized on a proprietary development project in the Diatron segment.

€ 000s	06.30.2022	12.31.2021	Change
Equity	204,413	205,759	-0.7%
Total assets	385,445	368,525	+4.6%
Equity ratio (%)	53.0	55.8	-280 bps

bps = basis points

LETTER FROM THE BOARD OF MANAGEMENT

Dear Shareholders, Partners and Friends of STRATEC,

The STRATEC Group has to report a reduction in its sales and earnings in the first half of 2022. The subdued momentum compared with the previous year was attributable in particular to high demand for laboratory capacities due to the situation in the previous year. As expected, this has not continued to the same extent in the new financial year. Furthermore, the recognition of sales for development projects has in some cases been postponed to the third quarter of 2022. The situation in the supply chain has also intensified further in recent months and led to significant delivery backlogs in the first half of the year. Assuming that the world manages to avoid any further trouble spots in the second half of the year, we nevertheless expect to be able to make up for part of these delivery backlogs by the end of the year. In view of this, and of forthcoming product launches and a lower overall basis of comparison with the previous year, we expect our sales and earnings performance to see a significant revival in the second half of 2022 already. We therefore expect to be able to reach the targets communicated for 2022.

In our development activities, we made notable advances with a whole series of projects in the first half of 2022. One particular current focus is on the preparations underway for the serial production of a molecular diagnostics system for one of the market leaders in this field. The market launch of this product by the partner is now imminent. Alongside the analyzer system, in this project STRATEC will also produce the complex polymerbased consumables needed to perform the tests and supply these to the partner.

Our company's long-term growth prospects are just as positive as ever, and are underpinned by our strong development pipelines. The expertise we have built up over the years, our reputation, and the trust placed by our customers in our performance capacity are the guarantors of our success. In the first half of 2022, we agreed numerous new cooperations with existing and new partners and are also holding promising negotiations for further projects.

We were also delighted to welcome numerous new employees to STRATEC's team once again in the first half of 2022. Overall, the STRATEC Group now has 1,429 employees (including temporary staff and trainees).

We would like to thank you, our shareholders, for your trust and for the high levels of approval you granted for individual agenda items once again at this year's Annual General Meeting. These included the approval of a further record dividend of € 0.95 per share, which we were then able to distribute in May 2022. This marks the eighteenth consecutive increase since payment of the first dividend in 2004.

Birkenfeld, August 2022

The Board of Management of STRATEC SE

Marcus Wolfinger Dr. Robert Siegle Dr. Claus Vielsack

INTERIM GROUP MANAGEMENT REPORT

Report on earnings, financial, and asset position

Earnings position

The STRATEC Group generated sales of € 137.2 million in the first half of 2022 (H1/2021: € 155.8 million). This corresponds to a year-on-year reduction of 11.9% (constant currency: -15.2%). This subdued sales performance is due in particular to the high basis of comparison in the Instrumentation and Diatron segments given the situation in the previous year. The second quarter of 2021 in particular saw exceptionally high demand for additional molecular diagnostic laboratory capacities, a development which, as expected, did not recur in the second quarter of 2022. Furthermore, the situation in the supply chain has intensified further in recent months and led to significant delivery backlogs in the first half of 2022. Moreover, the recognition of sales for development projects has in some cases been postponed to the third quarter of 2022.

Within the operating divisions, sales with Systems decreased by 23.6% in the first half of 2022 (constant currency: -26.6%), while sales with Service Parts and Consumables showed a reduction of 3.6% (constant currency: -7.0%). Notwithstanding the aforementioned postponement of the recognition of sales to the third quarter, sales with Development and Services increased by 51.6% (constant currency: +47.1%).

Consolidated sales by operating division (€ 000s)

	H1/2022	H1/2021	Change
Systems	73,133	95,748	-23.6% cc -26.6%
Service Parts & Consumables	46,832	48,602	-3.6% cc -7.0%
Development and Services	16,558	10,922	+51.6% cc +47.1%
Other	670	493	+35.9% cc +28.4%
Consolidated sales	137,193	155,765	-11.9% cc -15.2%

cc = constant currency

Given the lower volume of sales, gross profit (gross profit on sales) also decreased, in this case from € 49.1 million in the previous year's period to € 37.8 million in the first half of 2022. The gross margin thus amounted to 27.6% as of June 30, 2022 compared with 31.5% in the previous year.

As a result of the development pipeline, which remains well stocked, and the associated high level of development activity, gross development expenses rose to € 25.0 million in the first six months of 2022 (H1/2021: € 23.5 million).

Sales-related expenses increased from € 4.6 million in the previous year's period to € 5.0 million in the first half of 2022. General administration expenses also showed a slight increase to € 8.9 million, up from € 8.4 million in the previous year's period.

Adjusted EBIT for the first six months of 2022 amounted to € 21.2 million, compared with € 34.5 million in the previous year's period. Accordingly, the adjusted EBIT margin decreased by 670 basis points to 15.4% (H1/2021: 22.1%). Alongside negative economies of scale in connection with the lower volume of sales, this key figure was influenced in particular by a weaker product and sales mix. Furthermore, the margin was adversely affected by negative measurement items for currency hedges, as well as by higher input costs which, due to individual contractual agreements, can only be passed on to customers at a later point in time.

Given the lower level of operating earnings, adjusted consolidated net income also decreased, in this case by 41.6% from € 28.5 million in the previous year's period to € 16.7 million. Adjusted earnings per share (basic) for the first six months of 2022 amounted to € 1.38 (H1/2021: € 2.36). Unadjusted earnings per share (basic) stood at € 1.04 (previous year: € 2.08).

To facilitate comparison, the key earnings figures for the first half of 2022 have been adjusted to exclude amortization resulting from acquisition-related purchase price allocations and a provision recognized for expected tax back payments (including interest payments) for the period from 2014 to 2021 (tax expenses: € 2.3 million; interest expenses: € 0.2 million). The previous year's figures were additionally adjusted to exclude an impairment recognized on a proprietary development project in the Diatron segment.

A reconciliation of the adjusted figures with those reported in the consolidated statement of comprehensive income is presented in the following tables.

€ 000s	H1/2022	H1/2021
Adjusted EBIT	21,178	34,457
Adjustments • PPA amortization • Impairment	-1,844 0	-2,909 -1,049
EBIT	19,334	30,499

€ 000s	H1/2022	H1/2021
Adjusted consolidated net income	16,679	28,547
Adjusted earnings per share in € (basic)	1.38	2.36
Adjustments • PPA amortization • Impairment • Taxes on income • Interest expenses	-1,844 0 -2,019 -214	-2,909 -1,049 572 0
Consolidated net income	12,602	25,161
Earnings per share in € (basic)	1.04	2.08

Segments

The business activities of the STRATEC Group are divided into three reporting segments.

In its Instrumentation segment, STRATEC pools its business with designing and manufacturing fully automated analyzer systems, including service parts and consumables, for its clinical diagnostics and life sciences customers.

The Diatron segment comprises the business with systems, system components, consumables and tests in the lower throughput segment, including hematology, molecular diagnostics, and clinical chemistry.

The Smart Consumables segment includes the business with developing and manufacturing smart consumables in the fields of diagnostics, life sciences, and medical technology.

Instrumentation segment

Sales in the Instrumentation segment amounted to € 100.4 million in the first six months of 2022 (H1/2021: € 109.9 million). This reflects a reduction of 8.6% compared with the previous year's period (constant currency: -12.3%). Given the previous year's high pandemic-related basis of comparison, this segment witnessed a significant reduction in Systems sales. Furthermore, delivery backlogs arose on account of the ongoing highly tense situation in the supply chain. By contrast, sales with Service Parts and Consumables and with Development and Services increased. The adjusted EBIT margin for the first six months of 2022 decreased by 770 basis points to 12.6% (H1/2021: 20.3%). The margin was adversely affected by negative economies of scale, a normalization of the product and sales mix, measurement items for currency hedges, and higher input costs. Due to individual contractual requirements, the process of adjusting the prices of STRATEC products is in some cases still being implemented.

Diatron segment

The Diatron segment reported a reduction in sales by 25.5% from € 35.2 million in the previous year's period to € 26.2 million in the first half of the 2022 financial year. On a constant-currency basis, this corresponds to a 27.3% reduction in sales. The subdued sales performance was attributable in particular to high call-up figures for molecular diagnostics systems due to the pandemic in the previous year's period. As expected, this circumstance did not recur in the first half of 2022. The adjusted EBIT margin for the first half of 2022 amounted to 28.1% compared with 31.0% in the previous year's period.

Smart Consumables segment

At € 10.6 million, sales in the Smart Consumables segment in the first half of the 2022 financial year were approximately at the previous year's level (H1/2021: € 10.7 million). The adjusted EBIT margin stood at 11.3%, as against 11.9% in the first half of 2021.

Summary of reporting segment performance (in € 000s)

	H1/2022	H1/2021	Change
Instrumentation
Sales	100,423	109,873	-8.6% cc -12.3%
Adjusted EBIT	12,625	22,267	-43.3%
Adjusted EBIT margin	12.6%	20.3%	-770 bps
Diatron
Sales	26,219	35,206	-25.5 % cc -27.3%
Adjusted EBIT	7,364	10,916	-32.5%
Adjusted EBIT margin	28.1%	31.0%	-290 bps
Smart Consumables
Sales	10,551	10,686	-1.3% cc -4.9%
Adjusted EBIT	1,189	1,274	-6.7 %
Adjusted EBIT margin	11.3%	11.9%	-60 bps

cc = constant currency

bps = basis points

Financial position

The cash flow from operating activities for the first six months of 2022 amounted to € 24.8 million, compared with € 33.3 million in the previous year's period. This reduction was largely due to the lower level of consolidated net income. Furthermore, trade payables and other liabilities rose less markedly than in the previous year's period.

The cash flow from investing activities stood at € -7.9 million in the first six months of 2022, as against € -10.3 million in the first half of 2021. Compared with the previous year, this item showed a reduction in particular in the outflow of funds for property, plant and equipment, which fell from € 6.3 million in the previous year to € 3.6 million. Investments in intangible assets amounted to € 4.4 million, up from € 4.0 million in the previous year.

The investment ratio (investments in property, plant and equipment and intangible assets / sales) therefore amounted to 5.8% for the first six months (H1/2021: 6.7%) and fell slightly short of the corridor of 6.0% to 8.0% targeted for the 2022 financial year as a whole.

The cash flow from financing activities stood at € -14.9 million in the first half of 2022 (H1/2021: € -18.9 million) and mainly consisted of the dividend of € 11.5 million distributed to shareholders in May 2022 and net repayments of financial liabilities amounting to € 3.7 million.

Asset position

Total assets grew from € 368.5 million as of December 31, 2021 to € 385.4 million as of June 30, 2022.

Non-current assets rose to € 184.1 million as of June 30, 2022, up from € 180.5 million as of December 31, 2021. This growth was driven in particular by an increase in right-of-use assets from € 8.7 million to € 12.6 million.

Property, plant and equipment amounted to € 58.8 million as of June 30, 2022 and thus approximated to the figure of € 58.7 million reported as of December 31, 2021.

Current assets increased to € 201.4 million as of June 30, 2022, up € 13.4 million on figure of € 188.0 million as of December 31, 2021. This growth was mainly driven by an increase in inventories.

Cash and cash equivalents totaled € 48.8 million as of June 30, 2022, compared with € 47.2 million as of December 31, 2021. Changes on the equity and liabilities side of the balance sheet resulted in particular from the increase in current and non-current contract liabilities, which rose from a total of € 26.2 million as of December 31, 2021 to € 34.6 million as of June 30, 2022. Among other factors, this increase was attributable to prepayments received for development projects.

The equity ratio stood at 53.0% as of June 30, 2022 and thus fell slightly short of the figure of 55.8% reported as of December 31, 2021. This reduction was attributable in particular to the dividend of € 11.5 million distributed in May 2022.

Macroeconomic and sector-specific framework

Macroeconomic framework

In its Economic Outlook published in June 2022, the Organisation for Economic Cooperation and Development (OECD) forecast global GDP growth of 3% in 2022. To account for the war in Ukraine, the OECD has thus corrected its forecast for global economic growth significantly downwards compared with the forecast of 4.5% published in December 2021. For 2023, the OECD is now predicting growth of 2.8% rather than its previous forecast of 3.2%. The rise in inflation is stated as the reason for this correction. This was weakening purchasing power and thus holding back the revival in private consumer spending. Increased uncertainty, the sharp rise in energy prices, and ongoing supply shortages are also impairing several economic sectors, as well as private investments and exports. As a result of the war, the OECD expects inflation to be higher and more prolonged than previously assumed.

Virtually all economies are set to generate notably weaker growth than expected. Europe will suffer most clearly from the economic and social implications of the war. Numerous European countries are directly affected due to their energy imports and the inflow of refugees.

For the current year, the OECD is now forecasting economic growth of 2.5% for the US (previously: 3.7%), 1.9% for Germany (previously: 4.0%), and 2.6% for the euro area (previously: 4.3%).

As the OECD itself states, its outlook is subject to great uncertainty and involves significant downside risks. Sources of uncertainty include the duration of the war in Ukraine, including any possible further escalation. Furthermore, the pandemic is not yet over. More aggressive or contagious variants may circulate, while China's zero-Covid strategy may lead to further disruptions in supply chains.

Given its long-term project and product lifecycles, STRATEC and the decisions its customers take concerning joint development projects are only affected by macroeconomic fluctuations to a limited extent. Having said this, the macroeconomic climate nevertheless plays a major role in STRATEC's entrepreneurial activity and is therefore extensively factored into the company's assessments and planning.

Sector-specific framework

Based on various estimates, the in-vitro diagnostics (IVD) market will continue to generate very healthy and sustainable growth rates. According to different assessments, the global IVD market currently has a volume of more than USD 80 billion. Consistently aging populations, the increased prevalence of infectious diseases, and the growing importance of personalized treatment – these are important and sustainable drivers of growth in the market. Over and above that, the research being performed on innovative technologies, such as specific biomarkers, will create new opportunities for future market growth. Here, the various segments within IVD are showing different growth rates.

STRATEC particularly operates in those segments which are reporting above-average high growth rates. These include molecular diagnostics, for example, as well as highly sensitive processes within immunodiagnostics. STRATEC offers products and solutions in numerous important areas of IVD.

Report on forecasts and other statements concerning the company's expected development

The COVID-19 pandemic has once again underlined the great importance of in-vitro diagnostics solutions within global healthcare systems. Global megatrends, such as aging populations and the increasing numbers of chronic and infectious diseases, are also generating sustainable growth in demand for in-vitro diagnostics products. Furthermore, major technological advances and the increasing sensitivity of tests is opening up ever more areas of application for in-vitro diagnostics processes. In view of these factors, the long-term growth prospects in the target markets served by STRATEC's customers are assessed as positively as before. Not only that, STRATEC is benefiting from a general willingness on the part of its customers to outsource the development and production of automation solutions to specialist partners. This is reflected on the one hand in the large number of market launches implemented in recent years and on the other in the company's well-stocked development pipeline.

For the current financial year, STRATEC expects to make up in the coming months for the delivery backlogs that arose in the first half of 2022. In addition, the company's sales momentum in the second half of 2022 is expected to be boosted by product launches and by the lower overall basis of comparison with the previous year. In view of these factors and based on current orders and order forecasts from its customers, STRATEC can confirm its financial guidance for the 2022 financial year. On a constant-currency basis, sales are therefore still expected to match the previous year's figure. The adjusted EBIT margin is still forecast without amendment at around 16.5% to 18.5% (2021: 18.9%).

STRATEC expects total investments in property, plant and equipment in 2022 to correspond to 6.0% to 8.0% of sales (2021: 7.0%).

Depending on its ability to recruit adequate numbers of suitably qualified employees, STRATEC plans a further moderate expansion in its workforce in the years ahead in order to do justice to continuing high demand for development services. STRATEC's financial forecast is based on budgets that account for the specific features of its business model, as well as numerous internal and external factors, and that weight such factors in accordance with their significance. New order figures, our customers' forecasts, and their order behavior and stocking of service parts play a superordinate role here, as do the numbers of projects in development and negotiation. This forecast does not account for additional opportunities resulting from external growth. Given the long-term nature of its business relationships, macroeconomic developments are of subordinate significance for STRATEC. The macroeconomic factor is therefore weighted less prominently in the company's forecasts.

Opportunity and risk report

The risk management system forms an active part of STRATEC's corporate management and is largely based on three pillars. In the central early warning risk identification system, the risks facing the corporate divisions and the associated business environment are analyzed, evaluated and monitored. Furthermore, the risk management system also comprises an internal control system (IKS) and a compliance system, which additionally ensures compliance with relevant legal and industry-specific requirements.

Risk management covers all of the company's material operating and administrative departments. Due to developments in connection with the COVID-19 pandemic and the difficulty involved in planning price movements given the inflationary monetary policies pursued by central banks in recent years and the implications of the war in Ukraine, procurement and supply risks have increasingly come into focus in recent quarters. Various measures have therefore been implemented and developed further to safeguard STRATEC's ongoing ability to supply its customers and ensure transparent management of the corresponding activities in the relevant departments. The changes in underlying conditions in recent months nevertheless made themselves felt in significantly higher broker and logistics costs, as well as in delays to supplies due to the limited availability of critical materials and upstream products. These are also reflected in the form of a temporarily weaker margin. Based on rolling turnover and production planning, the company compiles financial and liquidity budgets and identifies and secures its internal financing requirements on this basis. This ensures that operating decisions, including the increased stocking policies currently in place, are consistent with the company's business performance. STRATEC counters volatile developments in relevant currencies, particularly the US dollar, by concluding currency hedges. Tax risks result from the implications of a tax audit conducted at the German parent company for the financial years 2014 to 2017. This risk has been countered by recognizting a provision of € 2.5 million for potential tax back payments, including interest expenses, for the period from 2014 to 2021.

The measures to contain the aforementioned risks will be upheld and tendencies towards an improvement in the overall situation are discernible. Despite this, any assessment of the further development in the risks associated with the COVID-19 pandemic, the war in Ukraine, and the further overall development in prices, as well as of the implications of these factors for STRATEC, remains subject to great uncertainty.

Alongside the risks referred to above, from STRATEC's perspective there were no further changes as of June 30, 2022 compared with the risks and opportunities identified for the 2022 financial year in the Group Management Report dated March 31, 2022. Details of our risk management system and our company's specific opportunity and risk profile and of our use of financial instruments can be found in Section 'D. Opportunities and Risks' in the 2021 Group Management Report.

CONSOLIDATED BALANCE SHEET as of June 30, 2022

Assets

€ 000s	06.30.2022	12.31.2021
Non-current assets
Goodwill	37,013	37,996
Other intangible assets	51,218	51,370
Right-of-use assets	12,611	8,720
Property, plant and equipment	58,788	58,738
Non-current financial assets	3,546	3,574
Non-current contract assets	18,311	18,208
Deferred taxes	2,600	1,902
	184,087	180,508
Current assets
Inventories	98,964	88,768
Trade receivables	37,884	37,184
Current financial assets	1,470	1,539
Current other receivables and assets	9,564	9,077
Current contract assets	3,834	4,053
Income tax receivables	830	212
Cash	48,812	47,184
	201,358	188,017
Total assets	385,445	368,525

Shareholders' equity and debt

€ 000s	06.30.2022	12.31.2021
Shareholders' equity
Share capital	12,131	12,128
Capital reserve	33,071	32,217
Revenue reserves	166,204	165,121
Treasury stock	-35	-35
Other equity	-6,958	-3,672
	204,413	205,759
Non-current debt
Non-current financial liabilities	84,694	83,774
Non-current contract liabilities	25,126	19,164
Provisions for pensions	5,658	5,373
Deferred taxes	10,000	8,788
	125,478	117,099
Current debt
Current financial liabilities	16,026	15,853
Trade payables	13,827	11,401
Current other liabilities	8,836	6,332
Current contract liabilities	9,450	7,040
Provisions	1,662	1,637
Income tax liabilities	5,753	3,404
	55,554	45,667
Total shareholders' equity and debt	385,445	368,525

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period January 1 to June 30, 2022

€ 000s	01.01. – 06.30.2022	01.01.–06.30.2021
Sales	137,193	155,765
Cost of sales	-99,356	-106,638
Gross profit	37,837	49,127
Research and development expenses	-3,967	-3,992
Sales-related expenses	-5,041	-4,561
General administrative expenses	-8,927	-8,356
Other operating income and expenses	-568	-1,719
Earnings before interest and taxes (EBIT)	19,334	30,499
Net financial expenses	-1,241	-713
Earnings before taxes (EBT)	18,093	29,786
Taxes on income	-5,491	-4,625
Consolidated net income	12,602	25,161
Items that may be subsequently reclassified to profit or loss:
Currency translation differences from translation of foreign operations	-3,286	1,223
Other comprehensive income (OCI)	-3,286	1,223
Comprehensive income	9,316	26,384
Basic earnings per share in €	1.04	2.08
No. of shares used as basis (basic)	12,126,743	12,101,550
Diluted earnings per share in €	1.03	2.07
No. of shares used as basis (diluted)	12,178,945	12,175,513

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME for the period April 1 to June 30, 2022

€ 000s 04.01. –06.30.2022 04.01. –06.30.2021 Sales 61,806 83,770 Cost of sales -46,585 -57,405 Gross profit 15,221 26,365 Research and development expenses -2,126 -2,310 Sales-related expenses -2,614 -2,393 General administrative expenses -4,557 -3,829 Other operating income and expenses -691 -1,462 Earnings before interest and taxes (EBIT) 5,233 16,371 Net financial expenses -701 -135 Earnings before taxes (EBT) 4,532 16,236 Taxes on income -3,099 -2,624 Consolidated net income 1,433 13,612 Items that may be subsequently reclassified to profit or loss: Currency translation differences from translation of foreign operations -3,645 2,617 Other comprehensive income (OCI) -3,645 2,617 Comprehensive income -2,212 16,229 Basic earnings per share in € 0,12 1.12 No. of shares used as basis (basic) 12,127,390 12,103,734 Diluted earnings per share in € 0,11 1.12 No. of shares used as basis (diluted) 12,175,626 12,170,939

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY for the period January 1 to June 30, 2021

€ 000s	Share capital	Capital reserve
As of 01.01.2021	12,103	29,866
Equity transactions with owners
• Dividend payments
• Issue of subscription shares from stock option programs, less costs of capital issue after taxes	11	540
Allocations due to stock option programs		423
Comprehensive income of the year
As of 06.30.2021	12,114	30,829

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY for the period January 1 to June 30, 2022

€ 000s	Share capital	Capital reserve
As of 01.01.2022	12,128	32,217
Equity transactions with owners
• Dividend payments
• Issue of subscription shares from stock option programs, less costs of capital issue after taxes	3	246
Allocations due to stock option programs		608
Comprehensive income of the year
As of 06.30.2022	12,131	33,071

Other equity

Other equity

		Other equity
Group equity	Currency translation	Pension plans		Treasury stock	Revenue reserves
172,545	-3,097	-2,314	-65		136,052
-10,888					-10,888
551
423
26,384	1,223				25,161
189,015	-1,874	-2,314	-65		150,325

		Other equity
Group equity	Currency translation	Pension plans	stock	Treasury	Revenue reserves
205,759	-1,592	-2,080	-35		165,121
-11,519					-11,519
249
608
9,316	-3,286				12,602
204,413	-4,878	-2,080	-35		166,204

CONSOLIDATED STATEMENT OF CASH FLOWS for the period January 1 to June 30, 2022

€ 000s	01.01. – 06.30.2022	01.01.–06.30.2021
I. Operations
Consolidated net income (after taxes)	12,602	25,161
Depreciation and amortization	8,507	9,775
Current income tax expenses	4,969	4,592
Income taxes paid less income taxes received	-3,304	-1,987
Financial income	-11	-75
Financial expenses	944	705
Interest paid	-760	-675
Interest received	9	49
Other non-cash expenses	4,343	2,921
Other non-cash income	-2,149	-1,164
Change in net pension provisions through profit or loss	146	179
Change in deferred taxes through profit or loss	522	33
Profit (-) / loss (+) on disposals of non-current assets	1	2
Increase (-) / decrease (+) in inventories, trade receivables and other assets	-12,122	-27,544
Increase (+) / decrease (-) in trade payables and other liabilities	11,058	21,297
Cash flow from operating activities	24,755	33,269
II. Investments
Incoming payments from disposals of non-current assets • Property, plant and equipment • Financial assets	17 23	33 24
Outgoing payments for investments in non-current assets • Intangible assets • Property, plant and equipment	-4,389 -3,574	-4,031 -6,339
Cash flow from investing activities	-7,923	-10,313
III. Financing
Incoming funds from taking up of financial liabilities	42,000	10,000
Outgoing payments for repayment of financial liabilities	-45,675	-18,589
Incoming payments from issue of shares for employee stock option programs	249	551
Dividend payments	-11,519	-10,888
Cash flow from financing activities	-14,945	-18,926
IV. Cash-effective change in cash (net balance I – III)	1,887	4,030
Cash at start of period	47,184	37,561
Impact of exchange rate movements	-259	-319
Cash at end of period	48,812	41,272

SELECT EXPLANATORY NOTE DISCLOSURES for the period January 1 to June 30, 2022

Information about the company

STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the STRATEC Group (hereinafter also 'STRATEC') offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance. The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

STRATEC SE, whose legal domicile is at Gewerbestrasse 37, 75217 Birkenfeld, Germany, is a publicly listed corporation under European law and is registered in the Commercial Register in Mannheim, Germany, with the number HRB 732007.

This half-year financial report was approved for publication by the Board of Management of STRATEC SE on August 10, 2022.

Basis of preparation

Consistent with § 115 (2) in conjunction with § 117 No. 2 of the German Securities Trading Act (WpHG), the half-year financial report of STRATEC SE comprises interim consolidated financial statements, an interim group management report, and a responsibility statement. The interim consolidated financial statements, which have not been audited, have been prepared in abridged form in accordance with the requirements of IAS 34 (Interim Financial Reporting) and in accordance with those International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), London, and interpretations issued by the International Financial Reporting Interpretations Committee (IFRS IC) that were valid and endorsed by the EU as of the reporting date and, in the case of the interim group management report, additionally in accordance with the applicable requirements of the German Securities Trading Act (WpHG).

The group currency is the euro (€). Unless otherwise indicated, all amounts have been stated in thousand euros (€ 000s). Due to numbers being rounded up or down, individual figures may not add up exactly to the totals stated and percentage figures may not correlate exactly with the absolute figures to which they refer.

Accounting policies applied

Apart from those accounting standards and interpretations requiring mandatory application for the first time in the current financial year and unless indicated otherwise below, the accounting policies applied in the interim consolidated financial statements are consistent with those applied in preparing the consolidated financial statements as of December 31, 2021. A detailed description of the accounting policies was published in the notes to the consolidated financial statements. Reference is made to the information provided in Section 'B. Accounting policies applied' in the 2021 Annual Report.

STRATEC has not made premature application of new or amended accounting standards and interpretations that have already been published but do not yet require mandatory application.

The following accounting standards and interpretations require mandatory application for the first time in the current financial year:

Standard	Title	Effective date1	EU endorsement
	New and amended standards and interpretations
IFRS 3	Amendments: Reference to the Conceptual Framework	01.01.2022	06.28.2021
IAS 16	Amendments: Proceeds before Intended Use	01.01.2022	06.28.2021
IAS 37	Amendments: Onerous Contracts: Cost of Fulfilling a Contract	01.01.2022	06.28.2021
Diverse	Annual Improvements to IFRS, 2018-2020 Cycle	01.01.2022	06.28.2021

1 For companies like STRATEC whose financial year corresponds to the calendar year

The application of these standards and interpretations in the current financial year is consistent with the respective transition requirements. Unless explicitly required by individual standards and interpretations and explained separately below, the respective requirements have generally been applied retrospectively, i.e. the information has been presented as if the new accounting methods had always been applied in the past. In these cases – and where called for by the respective standard – the comparative figures have been adjusted accordingly.

The aforementioned amendments did not have any implications for these interim consolidated financial statements.

Impairment tests

STRATEC performs impairment tests pursuant to IAS 36 (Impairment of Assets) on goodwill and other intangible assets with unlimited or indefinite useful lives, as well as on intangible assets not yet ready for use, at least once a year. Furthermore, impairment tests pursuant to IAS 36 (Impairment of Assets) are performed when specific indications of impairment arise on the basis of external and internal sources of information. Due to changes in the market climate and their implications for the costs of capital, STRATEC has reviewed its material intangible assets and, where necessary, calculated the recoverable amount for each asset or cash generating unit. The impairment tests did not result in the recognition of any impairments. In the previous year's reporting period, an impairment loss of € 1,049k was recognized on internally generated intangible assets relating to proprietary development projects. This impairment was allocable to the Diatron segment.

Scope of consolidation

In accordance with the requirements of IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of STRATEC SE (parent company) basically include all companies controlled by STRATEC SE (subsidiaries). Specifically, alongside STRATEC SE these comprise the following subsidiaries:

		Shareholding %
Company	Domicile 06.30.2022 12.31.2021
Germany
STRATEC Capital GmbH	Birkenfeld, Germany	100%	100%
STRATEC PS Holding GmbH	Birkenfeld, Germany	100%	100%
European Union
STRATEC Biomedical S.R.L.	Cluj-Napoca, Romania	100%	100%
STRATEC Consumables GmbH	Anif, Austria	100%	100%
RE Medical Analyzers Luxembourg 2 S.à r.l.	Bereldange, Luxembourg	100%	100%
Diatron Medicinai Instrumentumok Laboratóriumi Diagnosztikai Fejlesztö-Gyártó Zrt	Budapest, Hungary	100%	100%
Mod-n-More Kft.	Budapest, Hungary	100%	100%
Other
STRATEC Switzerland AG	Beringen, Switzerland	100%	100%
STRATEC Biomedical USA, Inc.	Medley, US	100%	100%
STRATEC Services AG	Beringen, Switzerland	100%	100%
Medical Analyzers Holding GmbH	Zug, Switzerland	100%	100%
STRATEC Biomedical Inc.	Medley, US	100%	100%
Diatron (US), Inc.	Medley, US	100%	100%

Due to its immaterial significance, the subsidiary STRATEC Biomedical (Taicang) Co. Ltd., Taicang, China, has not been included in the consolidated financial statements by way of full consolidation.

Segment disclosures

No changes in segmentation have arisen compared with the consolidated financial statements as of December 31, 2021.

Segment data by operating segment for the period from January 1 to June 30, 2022

	Instrumentation (includes service parts and consumables allocable to business unit) € 000s	Diatron (includes service parts and consumables allocable to business unit) € 000s	Smart Consumables € 000s	Total € 000s	Reconciliation1 € 000s	Total € 000s
Sales with external customers	100,423	26,219	10,551	137,193	0	137,193
Inter-segmental sales	759	2,827	417	4,003	-4,003	0
Depreciation, amortization, and impairments	4,862	1,689	1,956	8,507	0	8,507
EBITDA	17,487	8,113	2,241	27,841	0	27,841
Adjusted EBITDA	17,487	8,113	2,241	27,841	0	27,841
EBIT	12,625	6,424	285	19,334	0	19,334
Adjusted EBIT	12,625	7,364	1,189	21,178	0	21,178
Interest income	1,197	0	0	1,197	-1,186	11
Interest expenses	656	1,116	358	2,130	-1,186	944
Additions to non-current assets	5,583	6,350	1,373	13,306	0	13,306
Average number of employees	805	329	0	1,134	0	1,134

1With regard to the reconciliation of the figures adjusted for one-off items with the Group figures, reference is made to the information provided in the 'Report on earnings, financial, and asset position' in the Interim Group Management Report.

	Instrumentation (includes service parts and consumables allocable to	Diatron (includes service parts and consumables allocable to	Smart
	business unit) € 000s	business unit) € 000s	Consumables € 000s	Total € 000s	Reconciliation1 € 000s	Total € 000s
Sales with external customers	109,873	35,206	10,686	155,765	0	155,765
Inter-segmental sales	740	4,141	312	5,193	-5,193	0
Depreciation, amortization, and impairments	4,176	3,658	1,941	9,775	0	9,775
EBITDA	26,444	11,596	2,234	40,274	0	40,274
Adjusted EBITDA	26,444	11,596	2,234	40,274	0	40,274
EBIT	22,267	7,938	293	30,499	0	30,499
Adjusted EBIT	22,267	10,916	1,274	34,457	0	34,457
Interest income	1,254	0	20	1,274	-1,199	75
Interest expenses	463	1,088	353	1,904	-1,199	705
Additions to non-current assets	7,332	2,129	1,141	10,602	0	10,602
Average number of employees	781	301	173	1,255	0	1,255

Segment data by operating segment for the period from January 1 to June 30, 2021

1With regard to the reconciliation of the figures adjusted for one-off items with the Group figures, reference is made to the information provided in the 'Report on earnings, financial, and asset position' in the Interim Group Management Report.

Sales

The sales generated from contracts with customers in the period from January 1, 2022 to June 30, 2022 are structured as follows:

Segment	Instrumentation € 000s	Diatron € 000s	Smart Consumables € 000s	Total € 000s
Type of goods or services
Analyzer systems	58,869	14,264	0	73,133
Service parts and consumables	30,530	11,264	5,038	46,832
Development and services	10,946	113	5,499	16,558
Other	78	578	14	670
Total	100,423	26,219	10,551	137,193
Geographical regions
Germany	17,515	6,531	210	24,256
European Union	45,580	8,249	3,161	56,990
Other	37,328	11,439	7,180	55,947
Total	100,423	26,219	10,551	137,193
Time at which sales are recognized
Recognized at a point in time	100,045	26,219	9,965	136,229
Recognized over time	378	0	586	964
Total	100,423	26,219	10,551	137,193

The sales generated from contracts with customers in the period from January 1, 2021 to June 30, 2021 are structured as follows:

Segment	Instrumentation € 000s	Diatron € 000s	Smart Consumables € 000s	Total € 000s
Type of goods or services
Analyzer systems	73,489	22,259	0	95,748
Service parts and consumables	28,986	12,335	7,281	48,602
Development and services	7,280	243	3,399	10,922
Other	118	369	6	493
Total	109,873	35,206	10,686	155,765
Geographical regions
Germany	13,889	9,810	269	23,968
European Union	53,176	9,494	2,891	65,561
Other	42,808	15,902	7,526	66,236
Total	109,873	35,206	10,686	155,765
Time at which sales are recognized
Recognized at a point in time	107,507	35,206	9,886	152,599
Recognized over time	2,366	0	800	3,166
Total	109,873	35,206	10,686	155,765

Research and development expenses

Research and development expenses not meeting the criteria for capitalization pursuant to IAS 38 (Intangible Assets) totaled € 4.0 million in the first six months of the 2022 financial year (previous year: € 4.0 million) and mainly involved personnel expenses and cost of materials. Overall, the STRATEC Group invested a total of € 25.0 million in research and development in the first six months of the 2022 financial year (previous year: € 23.5 million).

Taxes on income

Taxes actually paid or owed in individual countries and deferred taxes are reported as taxes on income. Interest on tax-related back payments and refunds is reported under other financial expenses.

Tax uncertainties mainly involve differences of opinion between the German tax authorities and STRATEC relating to a tax audit conducted for the financial years 2014 to 2017 and particularly pertaining to the appropriateness of transfer prices.

Where, based on STRATEC's assessment, the disputed items will in all likelihood be utilized, provisions have been recognized at the most likely amount of utilization or the expected value pursuant to IFRIC 23 (Uncertainty over Income Tax Treatments). In the period under report, STRATEC recognized expenses of € 2,329k for this purpose in taxes on income and expenses of € 214k in net financial expenses. These expenses relate to the financial years 2014 to 2021.

Intangible assets and property, plant and equipment

STRATEC invested a total of € 7,963k in intangible assets and property, plant and equipment in the first six months of the 2022 financial year (previous year: € 10,370k).

Investments in intangible assets mainly relate to the capitalization of development expenses, while investments in property, plant and equipment chiefly involve the acquisition of building fittings, machinery, tools, and test materials.

Financial instruments

The following table presents the carrying amounts of individual financial assets and liabilities for each individual class of financial instruments pursuant to IFRS 9 (Financial Instruments) and reconciles these with the corresponding balance sheet items. The 'Fair value in scope of IFRS 7' column presents the fair values of all financial instruments recognized in the interim consolidated financial statements that are in the scope of IFRS 7 (Financial Instruments: Disclosures) and which were not recognized at fair value. The short maturities of current financial assets and liabilities mean that their fair values approximate to their carrying amounts.

	Measured at amortized	Measured at fair value				Not in scope of IFRS 9	Carrying amount in	Fair value in scope of
06.30.2022	cos		through profit or loss				balance sheet	IFRS 7
(12.31.2021)		of which Level 1	of which Level 2	of which Level 3	through OCI
	€ 000s	€ 000s	€ 000s	€ 000s	€ 000s	€ 000s	€ 000s	€ 000s
Non-current assets
Financial assets	3,446 (3,474)					100 (100)	3,546 (3,574)	3,446 (3,474)
Current assets
Trade receivables	37,884 (37,184)						37,884 (37,184)	37,884 (37,184)
Financial assets	551 (313)	919 (1,226)					1,470 (1,539)	551 (313)
Cash	48,812 (47,184)						48,812 (47,184)	48,812 (47,184)
Total financial assets	90,693 (88,155)	919 (1,226)	0 (0)	0 (0)	0 (0)	100 (100)	91,712 (89,481)
Non-current debt
Financial liabilities	71,795 (74,701)		497 (0)			12,402 (9,073)	84,694 (83,774)	70,967 (74,655)
Current debt
Financial liabilities	11,425 (11,256)		2,010 (234)			2,591 (4,363)	16,026 (15,853)	12,125 (12,032)
Trade payables	13,827 (11,401)						13,827 (11,401)	13,827 (11,401)
Total financial liabilities	97,047 (97,358)	0 (0)	2,507 (234)	0 (0)	0 (0)	14,993 (13,436)	114,547 (111,028)

Fair value hierarchy

To enhance the comparability and consistency of fair value measurements and related disclosures, IFRS 13 (Fair Value Measurement) stipulates a fair value hierarchy that allocates the input factors used in valuation methods to calculate fair value to three levels. The hierarchy grants the highest priority to prices (taken over without amendment) on active markets for identical assets or liabilities (Level 1 input factors) and the lowest priority to non-observable input factors (Level 3 input factors). The following specific definitions apply:

Input factors: Assumptions that would be used by market participants when determining the price of an asset or liability, including risk assumptions, such as:

• (a) The risk involved in a specific valuation method used to calculate fair value (such as a price model), and
• (b) The risk involved in the input factors used in the valuation method.

Input factors may be observable or non-observable.

Level 1 input factors: Listed prices (taken over without amendment) on active markets for identical assets or liabilities to which the company has access on the valuation date.

Level 2 input factors: Input factors other than the listed prices included in Level 1 that are either directly or indirectly observable for the asset or liability.

Level 3 input factors: Input factors not observable for the asset or liability.

Observable input factors: Input factors derived from market data, such as publicly available information about actual events or transactions, which reflect those assumptions that would be used by market participants when determining the price of the asset or liability.

Non-observable input factors: Input factors for which no market data is available and which are derived from the best information available concerning the assumptions that would be used by market participants when determining the price of the asset or liability.

No items were reclassified within the three input factor levels in the period from January 1 to June 30, 2022 or in the comparative period. The financial assets allocated to Level 1 involve shares in listed companies, which have been measured at the closing price on the stock market with the highest trading volumes as of the balance sheet date. The financial liabilities allocated to Level 2 involve forward exchange transactions intended to hedge currency risks. Overall, this had the following implications for the consolidated statement of comprehensive income:

Level 1	Level 2	Level 3
1,248	1,226	0
		0
		0 0
		0
		0
0	0	0
		0
		0
0	0	0
1,166	-405	0
1,226	-234	0
		0
		0
-307	0	0
		0
		0
0	0	0
		0 0
0	-87	0
919	-2,507	0
	0 0 -82 0 0 0 0 0 0 0 0 0 0	0 -1,631 0 0 0 0 0 0 -2,186 0 0 0 0

Financial liabilities

Financial liabilities include liabilities to banks of € 73,182k (12.31.2021: € 75,835k). Of this total, € 35.0 million (12.31.2021: € 36.0 million) involve liabilities in connection with a master credit facility with a revolving credit line of up to € 55.0 million (12.31:2021: € 70.0 million). On January 24, 2022, the existing master credit facility concluded with three banks and a term through to January 31, 2023 was prematurely replaced by a new master credit facility with four banks and a term through to January 22, 2027. The financing contracts in some cases include agreements concerning compliance with specific key financial figures (covenants) and general obligations involving restrictions on the disposability of assets and provisos concerning further borrowing. Of the liabilities to banks, € 35.0 million have floating interest rates (12.31.2021: € 36.0 million).

Furthermore, financial liabilities include the total obligation of € 1,253k (12.31.2021: € 3,976k) stated for expected payments in connection with stock appreciation rights (SARs) granted. In the period under report, income of € 870k was recognized through profit or loss for cash-settled share-based payments (previous year: expenses of € 753k).

The fair value of stock appreciation rights (SARs) developed as follows:

Stock appreciation rights (SARs)	Tranche 1/2022	Tranche 1/2021
Issue date	01.25.2022	03.08.2021
Fair value at issue date	€ 37.45	€ 38.05
Fair value at 06.30.2021	n/a	€ 44.16
Fair value at 12.31.2021	n/a	€ 54.40
Fair value at 06.30.2022	€ 21.59	€ 20.17

The development in the number of stock appreciation rights (SARs) is presented below:

Number of rights	Total at 01.01.2022	Granted	Exercised/lapsed/ forfeited	Total at 06.30.2022	of which exercisable
Tranche 1/2020	30,000	0	30,000	0	0
Tranche 1/2021	30,000	0	0	30,000	0
Tranche 1/2022	0	30,000	0	30,000	0
Total	60,000	30,000	0	60,000	0

Risk management activities

STRATEC's assets, liabilities and future activities are subject to liquidity risks, default risks, and market risks resulting from changes in exchange rates, interest rates and stock market prices.

The allowances recognized for expected credit losses on trade receivables are structured as follows:

€ 000s	Carrying amount	of which: not overdue at balance sheet date	of which: overdue at balance sheet date within following time bands
			up to 30 days	between 30 and 90 days	more than 90 days
06.30.2022	38,796	32,316	3,286	2,159	1,035
Expected credit loss			228	99	598
12.31.2021	38,256	27,988	228 6,966	1,469	1,833
Expected credit loss			228	90	767

Furthermore, allowances of € 28k were recognized as of June 30, 2022 for expected credit losses on contract assets (12.31.2021: € 39k).

STRATEC had concluded hedging transactions as of June 30, 2022. These involve currency futures intended to hedge future cash flows from sales in USD. No use was made of the hedge accounting provisions of IFRS 9 (Financial Instruments).

Shareholders' equity

The development in shareholders' equity at STRATEC and dividends paid is presented in the consolidated statement of changes in equity. The number of ordinary shares issued by STRATEC SE as of June 30, 2022 amounts to 12,131,495 (previous year: 12,114,395; 12.31.2021: 12,127,995). All shares are fully paid in and are registered shares.

Treasury stock holdings

The company owned a total of 1,899 treasury stock shares at the interim balance sheet date. This corresponds to a prorated amount of € 1,899.00 of the company's share capital and to a 0.02% share of its equity.

Stock option programs

The company had two stock option programs (equity-settled share-based payment) as of June 30, 2022.

In the financial years 2015 to 2017, the individual members of the Board of Management were not granted any stock options, but rather received stock appreciation rights (cash-settled share-based payment – SARs) as a variable compensation component of a long-term incentive nature. From the 2018 financial year, a modification to this approach means that the company no longer exclusively grants stock appreciation rights (SARs), but has once again granted stock options at a ratio of 75% (SARs) to 25% (stock options).

The following option schedule provides a summary of the development in stock option rights in the period under report:

Stock option rights	Board of Management No. of options	Employees No. of options	Total No. of options
Outstanding on 01.01.2022 • of which exercisable	40,000 0	128,150 0	168,150 0
Granted	8,778	19,000	27,778
Exercised	0	3,500	3,500
Lapsed	0	0	0
Forfeited	0	0	0
Outstanding on 06.30.2022 • of which exercisable	48,778 0	143,650 1,500	192,428 1,500

Components of other comprehensive income (OCI)

The currency translation reserve of € -4,878k recognized within other comprehensive income (OCI) as of June 30, 2022 (previous year: € -1,874k; 12.31.2021: € -1,592k) mainly comprises currency differences arising upon the translation of the separate financial statements of companies whose functional currency is not the euro and from the translation within equity of groupinternal net investments as of the reporting date. The change in this item is recognized in the 'Currency translation differences from translation of foreign business operations' line item in the statement of comprehensive income.

Select related-party disclosures

In the first half of 2022, STRATEC SE purchased services of € 77k from STRATEC Biomedical (Taicang) Co. Ltd. (previous year: € 110k). As of the interim reporting date, there were receivables of € 13k (12.31.2021: € 13k) and liabilities of € 25k (12.31.2021: € 25k).

Mod-n-More Kft. purchased services of € 71k from STRATEC Biomedical (Taicang) Co. Ltd. in the first half of 2022 (previous year: € 98k). As of the interim reporting date, there were liabilities of € 55k in this respect (12.31.2021: € 30k).

By resolution of the Annual General Meeting on May 20, 2022, Prof. Dr. Georg Heni, resident in Freudenstadt and a German public auditor, tax advisor, graduate in business administration, and Managing Partner of WirtschaftsTreuhand GmbH and Dr. med. Patricia Geller, resident in Heidelberg and a Management Board member at Limbach Gruppe SE, were elected as members of the Supervisory Board with effect from the conclusion of the 2022 Annual General Meeting. Due to the Commercial Register entry required to amend the Articles of Association in respect of the increase in the number of Supervisory Board members, the election of Dr. med. Patrica Geller was subject to conditions precedent. This entry was made in the Commercial Register on June 10, 2022. As planned, Dr. Rudolf Eugster retired from the Supervisory Board upon the conclusion of the 2022 Annual General Meeting.

As of June 30, 2022, STRATEC reported outstanding balances of € 2,408k in connection with profit participation by members of the Board of Management (12.31.2021: € 6,021k).

Employees

Including temporary employees, STRATEC had a total of 1,427 employees as of June 30, 2022 (previous year: 1,398: 12.31.2021: 1,396).

Major events after the interim reporting date

No events of particular significance which can be expected to materially influence the Group's earnings, financial, or asset position have occurred since the interim reporting date.

Responsibility statement

We hereby affirm that, to the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group consistent with the principles of proper accounting, and the interim group management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

FINANCIAL CALENDAR

Subject to amendment.

Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

IMPRINT AND CONTACT

Published by

STRATEC SE Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 7082 7916-0 info@stratec.com www.stratec.com

Head of Investor Relations, Sustainability & Corporate Communications Jan Keppeler Phone: +49 7082 7916-6515 j.keppeler@stratec.com

Notice

Forward-looking statements involve risks: This half-year financial report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This half-year financial report contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this half-year financial report on account of mathematical rounding up or down in the course of addition.

This half-year financial report is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.